Update information

June 2018: Recommendations 1.1 and 1.2 have been amended to clarify that they refer to monotherapy. Recommendation 1.3 has been updated and replaced by recommendation 1.5.5 in the NICE guideline on dementia.

May 2016: Recommendation 1.3 in this technology appraisal has been partially updated by recommendation in the NICE guideline on dementia (NICE guideline CG42). Specifically:

  • non-specialists can now prescribe donezepil, galantamine, rivastigmine and memantine, as long as they have taken advice from a clinician who has the necessary knowledge and skills. This includes:

    • secondary care medical specialists such as psychiatrists, geriatricians and neurologists

    • other healthcare professionals such as GPs, nurse consultants and advanced nurse practitioners with specialist expertise in diagnosing and treating Alzheimer's disease

  • local arrangements for prescribing, supply, and treatment review should follow the NICE guideline on medicines optimisation (NICE guideline NG5).

February 2014: Implementation section updated to clarify that donepezil, galantamine, rivastigmine and memantine are recommended as options for treating Alzheimer's disease. Additional minor maintenance update also carried out.

ISBN: 978-1-4731-1898-0

  • National Institute for Health and Care Excellence (NICE)